STOCK TITAN

Ocular Therapeut - OCUL STOCK NEWS

Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.

Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.

Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) announced it will report its first quarter financial results for the period ending March 31, 2022, on May 9, 2022. Following the earnings release, the management team will host a conference call at 4:30 PM ET to discuss the financial results and provide a business update. Investors can access the live webcast via the company’s investor section of its website. Ocular Therapeutix focuses on developing innovative therapies for eye diseases, including its FDA-approved product DEXTENZA®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences earnings
-
Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL) announced its participation in the ARVO Annual Meeting from May 1-4 in Denver, presenting key clinical and pre-clinical data from its eye disease therapies. The company highlighted its hydrogel platform's potential to enhance treatment efficacy and reduce complexities in managing eye diseases. Notable presentations include results on OTX-DED for dry eye disease and OTX-TKI for retinal diseases. The company remains optimistic about advancing its pipeline and addressing unmet medical needs in ophthalmology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
conferences clinical trial
-
Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL) announced a strong presence at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company showcased updates on DEXTENZA, an FDA-approved treatment for ocular inflammation and allergic conjunctivitis, along with the OTX-DED for dry eye disease. Multiple presentations highlighted the efficacy of these therapies, underscoring the potential of Ocular Therapeutix's hydrogel technology to address unmet needs in ophthalmic care. The meeting is set for April 22-26, 2022, in Washington, D.C.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
conferences clinical trial
Rhea-AI Summary

AffaMed Therapeutics announced the approval of DEXTENZA in Macau, China, for treating ocular inflammation and pain post-ophthalmic surgery. This approval follows a licensing agreement with Ocular Therapeutix (NASDAQ: OCUL) for its development in Greater China, South Korea, and some ASEAN markets. DEXTENZA is already FDA-approved for similar indications in the U.S. The product is notable as the first sustained-release intracanalicular insert in Macau, allowing for a preservative-free dose of dexamethasone for 30 days with a single administration. Future expansion of indications is planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
Rhea-AI Summary

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that CEO Antony Mattessich will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:10 AM EDT. The management team will also hold investor meetings during the event. Interested investors can schedule meetings through their Cowen representatives. A live webcast of the presentation will be available on the company's website. Ocular Therapeutix specializes in innovative therapies for eye conditions, including its FDA-approved product, DEXTENZA, and its ongoing clinical trials for various ophthalmic treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
-
Rhea-AI Summary

Ocular Therapeutix reported Q4 2021 financial results, highlighting net sales of DEXTENZA® at $12.2 million, a 77% year-over-year increase, despite challenges from the Omicron variant. The establishment of a dedicated business unit for DEXTENZA aims to enhance its market presence. The company also completed enrollment for the U.S. clinical trial of OTX-TKI, with data expected in late 2022. Overall, net loss narrowed to $(3.9 million) from $(85.6 million), reflecting improved financial health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
Rhea-AI Summary

Ocular Therapeutix, Inc. (Nasdaq: OCUL) will release its fourth quarter and year-end financial results on February 28, 2022, after market close. A live conference call will follow at 4:30 p.m. ET to discuss results and provide business updates. The call can be accessed via their website or through provided phone numbers. The company focuses on innovative eye therapies, including the FDA-approved DEXTENZA®. Their pipeline includes OTX-TKI and OTX-TIC, both in clinical trials for various eye conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences earnings
-
Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL) announced its intention to present data from two Phase 1 clinical trials at upcoming medical meetings. The data on OTX-TKI, an axitinib implant for wet AMD, will be shared at the Angiogenesis Meeting on February 12, 2022. Meanwhile, OTX-TIC, a travoprost implant for glaucoma, will be presented at the Glaucoma360 Meeting on February 11, 2022. The interim data highlighted safety and efficacy, with over 60% of OTX-TKI subjects showing extended activity over six months. The company aims to begin a Phase 2 trial for OTX-TIC soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences clinical trial
-
Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL) has announced the dosing of its first patient in a real-world study in China, evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for treating ocular inflammation and pain post-cataract surgery. This trial aims to enroll about 120 patients and assess key endpoints at Days 8 and 14. Ocular entered a licensing agreement with AffaMed Therapeutics in 2020, receiving an upfront payment of $12 million and the potential for up to $91 million in milestone payments. The ophthalmology market in China is valued at $5 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
Rhea-AI Summary

Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The management team will also host virtual investor meetings during the event. A pre-recorded presentation will be available from 7:00 AM ET on January 10 and can be accessed on the Company's investors section of its website, with a replay available for 90 days. Ocular Therapeutix focuses on innovative therapies for eye conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
conferences
Ocular Therapeut

Nasdaq:OCUL

OCUL Rankings

OCUL Stock Data

1.16B
152.15M
1.01%
85.07%
7.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD